Literature DB >> 27558095

Novel FBN1 mutations are responsible for cardiovascular manifestations of Marfan syndrome.

Jin'e Wang1,2, Yupeng Yan2, Jinxing Chen2, Ling Gong2, Yu Zhang2, Mengmeng Yuan2, Bing Cui2, Yibo Wang3.   

Abstract

The fibrillin-1 (FBN1) gene mutations result in Marfan syndrome (MFS) and have a variety of phenotypic variations. This disease is involved in the skeletal, ocular and cardiovascular system. Here we analyzed genotype-phenotype correlation in two Chinese families with MFS. Two patients with thoracic aortic aneurysms and dissections were diagnosed as MFS according to the revised Ghent criteria. Peripheral blood samples were collected and genomic DNAs were isolated from available cases, namely, patient-1 and his daughter and son, and patient-2 and his parents. According to the next-generation sequencing results, the mutations in FBN1 were confirmed by direct sequencing. A heterozygous frameshift mutation in exon 12 of FBN1 was found in the proband-1 and his daughter. They showed cardiovascular phenotype thoracic aortic aneurysms and dissections, a life-threatening vascular disease, and atrial septal defect respectively. One de novo missense mutation in exon 50 of FBN1 was identified only in the patient-2, showing aortic root aneurysm and aortic root dilatation. Intriguingly, two novel mutations mainly caused the cardiovascular complications in affected family members. No meaningful mutations were found in these two patients by screening all exons of 428 genes related with cardiovascular disease. The high incidence of cardiovascular manifestations might be associated with the two novel mutations in exon 12 and 50 of FBN1.

Entities:  

Keywords:  FBN1; Genotype; Marfan syndrome; Phenotype

Mesh:

Substances:

Year:  2016        PMID: 27558095     DOI: 10.1007/s11033-016-4067-y

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  26 in total

Review 1.  Marfan's syndrome.

Authors:  Daniel P Judge; Harry C Dietz
Journal:  Lancet       Date:  2005-12-03       Impact factor: 79.321

2.  Solution structure of a pair of calcium-binding epidermal growth factor-like domains: implications for the Marfan syndrome and other genetic disorders.

Authors:  A K Downing; V Knott; J M Werner; C M Cardy; I D Campbell; P A Handford
Journal:  Cell       Date:  1996-05-17       Impact factor: 41.582

Review 3.  Recent progress in genetics of Marfan syndrome and Marfan-associated disorders.

Authors:  Takeshi Mizuguchi; Naomichi Matsumoto
Journal:  J Hum Genet       Date:  2006-10-24       Impact factor: 3.172

4.  Determination of the molecular basis of Marfan syndrome: a growth industry.

Authors:  Peter H Byers
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

Review 5.  Biogenesis and function of fibrillin assemblies.

Authors:  Francesco Ramirez; Lynn Y Sakai
Journal:  Cell Tissue Res       Date:  2009-06-10       Impact factor: 5.249

Review 6.  Current insights in diagnosis and management of the cardiovascular complications of Marfan's syndrome.

Authors:  Gijs J Nollen; Maarten Groenink; Ernst E van der Wall; Barbara J M Mulder
Journal:  Cardiol Young       Date:  2002-07       Impact factor: 1.093

Review 7.  Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database.

Authors:  Gwenaëlle Collod-Béroud; Saga Le Bourdelles; Lesley Ades; Leena Ala-Kokko; Patrick Booms; Maureen Boxer; Anne Child; Paolo Comeglio; Anne De Paepe; James C Hyland; Katerine Holman; Ilkka Kaitila; Bart Loeys; Gabor Matyas; Lieve Nuytinck; Leena Peltonen; Terhi Rantamaki; Peter Robinson; Beat Steinmann; Claudine Junien; Christophe Béroud; Catherine Boileau
Journal:  Hum Mutat       Date:  2003-09       Impact factor: 4.878

8.  A compound-heterozygous Marfan patient: two defective fibrillin alleles result in a lethal phenotype.

Authors:  L Karttunen; M Raghunath; L Lönnqvist; L Peltonen
Journal:  Am J Hum Genet       Date:  1994-12       Impact factor: 11.025

9.  Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study.

Authors:  L Faivre; G Collod-Beroud; B L Loeys; A Child; C Binquet; E Gautier; B Callewaert; E Arbustini; K Mayer; M Arslan-Kirchner; A Kiotsekoglou; P Comeglio; N Marziliano; H C Dietz; D Halliday; C Beroud; C Bonithon-Kopp; M Claustres; C Muti; H Plauchu; P N Robinson; L C Adès; A Biggin; B Benetts; M Brett; K J Holman; J De Backer; P Coucke; U Francke; A De Paepe; G Jondeau; C Boileau
Journal:  Am J Hum Genet       Date:  2007-07-25       Impact factor: 11.025

10.  Premature termination mutations in FBN1: distinct effects on differential allelic expression and on protein and clinical phenotypes.

Authors:  Iris Schrijver; Wanguo Liu; Raanan Odom; Thomas Brenn; Peter Oefner; Heinz Furthmayr; Uta Francke
Journal:  Am J Hum Genet       Date:  2002-06-14       Impact factor: 11.025

View more
  3 in total

1.  Identification of Novel Causal FBN1 Mutations in Pedigrees of Marfan Syndrome.

Authors:  Yueli Wang; Xiaoyan Li; Rongjuan Li; Ya Yang; Jie Du
Journal:  Int J Genomics       Date:  2018-04-17       Impact factor: 2.326

2.  Exome Sequencing Identifies a Novel FBN1 Variant in a Pakistani Family with Marfan Syndrome That Includes Left Ventricle Diastolic Dysfunction.

Authors:  Nadia Farooqi; Louise A Metherell; Isabelle Schrauwen; Anushree Acharya; Qayum Khan; Liz M Nouel Saied; Yasir Ali; Hamed A El-Serehy; Fazal Jalil; Suzanne M Leal
Journal:  Genes (Basel)       Date:  2021-11-28       Impact factor: 4.096

3.  CRISPR/Cas9 in zebrafish: An attractive model for FBN1 genetic defects in humans.

Authors:  Xiaoyun Yin; Jianxiu Hao; Yuanqing Yao
Journal:  Mol Genet Genomic Med       Date:  2021-07-29       Impact factor: 2.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.